Titlebook: Novel Therapeutics for Rare Lymphomas; Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra

Prosaic

Anaplastic Large Cell Lymphoma,nts targeting the universally expressed surface receptor on ALCL cells, CD30, and the ALK tyrosine kinase receptor inhibitors have provided patients with relapsed or refractory ALCL more effective treatment options.

Lymphocyte

Book 2020 on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule

羽毛長(zhǎng)成

Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,onmalignant tissues, CD30 has become the focus for innovative therapeutic advances (Horie, Semin Immunol 10(6):457–470, 1998). This chapter will focus on first reviewing the standard of care for CD30+ lymphomas and then describing the recent developments in CD30-directed immunotherapy.

外來(lái)

HILAR

單調(diào)女

catagen

Novel Agents in Primary Central Nervous System Lymphoma,ivolumab, and lenalidomide have shown promise in PCNSL. Future directions will include larger studies with these agents, as well as combination studies with novel agents and conventional chemotherapy.

BRAVE

Enrage

Extranodal NK/T-Cell Lymphoma,ocalized disease include concurrent, sandwich, or sequential chemoradiation. Advanced stage and extranodal disease are treated with chemotherapy. The overall prognosis for ENKTCL has improved with asparaginase-based chemotherapy. In the relapsed and/or refractory setting, several promising novel agents are currently under investigation.

vascular

Enteropathy-Associated T-Cell Lymphomas,s are significantly better for those who receive anthracycline-based chemotherapy, some patients are not candidates for systemic therapy and have particularly poor outcomes. There is no standard approach to the management of EATL and MEITL. Novel therapies hold promise for the future.